Here's a post from In the Pipeline discssing latest information on status of VC investment in biopharm R&D with start ups in India and China. Conclusion? VC activity is still fairly low by comparison to US standards. The study author's estimate was that approximately $1.7 B had been invested in 116 firms over the past 12-13 years. By comparison, the US industry would expect about that much investment activity per quarter.
No where to go but up -- and that does appear to be the direction in which things are moving -- albeit slower perhaps than one might imagine.
Posted by Bruce Lehr Mar 8th 2013.